Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study.
JSON
Ekberg S, Molin D, Pahnke S, Bergström F, Brånvall E, Smedby KE, Wästerlid T
Acta Oncol 63 (-) 164-168 [2024-04-09; online 2024-04-09]
The COVID-19 pandemic posed a large challenge for healthcare systems across the world. Comprehensive data on the impact of the COVID-19 pandemic on incidence and mortality in lymphoma are lacking. Using data from the Swedish lymphoma register, we compare incidence and 1-year survival of lymphoma patients in Sweden before (2017-2019) and during the pandemic (2020 and 2021). Fewer patients were diagnosed with lymphomas during March-June 2020, but the annual incidence rates for 2020 and 2021 were similar to those of 2017-2019. A larger proportion of patients presented with stage IV disease during 2021. There were no differences in other base-line characteristics nor application of active treatment in pre-pandemic and pandemic years. One-year overall survival was not inferior among lymphoma patients during the pandemic years compared to pre-pandemic years i.e., 2017-2019. The COVID-19 pandemic had limited impact on the incidence and mortality of lymphoma in Sweden.
Topics: Register-based research
PubMed 38591352
DOI 10.2340/1651-226X.2024.35238
Crossref 10.2340/1651-226X.2024.35238